CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities 
Summit Announces Closing of Private Placement of $50 Million
Summit Therapeutics Inc.(“Summit” or the “Company”) Summit Announces Closing of Private Placement of $50 Million Cambridge, MA, November 6, 2020...
Tauriga Sciences, Inc. Experiencing Greater Market Acceptance for its Cannabis (CBD & CBG) Infused Chewing Gum Product Line
NOV 6 PR Complete Tauri-Gum™ Product Line (6 Flavors) The Recent Improvements to the U.S. Legal and Regulatory Landscape Have...
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU
- Marked Reductions in Phe Observed at Two Doses - - Achieved Goal with Plans to Advance to Randomized, Concurrently...
N.M. Medical Cannabis Program on Track to Break $200M Before Year End
Third-quarter patient sales up 62% over same period last year, COVID-19 continues to impact demand New Mexico Medical Cannabis Program...
Trading in Novo Nordisk shares by board members, executives and associated persons on 4 and 5 November 2020
Bagsværd, Denmark, 6 November 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by...
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference
Statistically significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital...
Virbac : Declaration of the number of shares and voting rights October 2020
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares...
ReWalk Robotics to Report Third Quarter 2020 Financial Results on November 10, 2020
MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILIT, Israel, Nov. 06, 2020 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”...
Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol
DOYLESTOWN, Pa., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem...
Genesis Healthcare to Release Third Quarter 2020 Results and Provide COVID-19 Update
KENNETT SQUARE, Pa., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Genesis HealthCare (NYSE:GEN) (Genesis or the Company), one of the nation’s...
SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
In October, SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected...
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to...
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date Complete response...
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of...
Atreca to Present at Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on...
Sientra to Participate in Upcoming Virtual Investor Conferences
SANTA BARBARA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical...
ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
-- Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal...
Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan
Experienced Financial Executive Brings Leadership and Public Company Expertise BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq:...
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense...
Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K
– Manuscript highlights the importance of molecular surveillance of SARS-CoV-2 immune evasion and rational design of vaccines and antibody therapies...